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Exercise-induced hypoxia is an index of the severity of interstitial
lung disease. We hypothesized that desaturation during a 6-minute
walk test would predict mortality for patients with usual interstitial
pneumonia (n  83) and nonspecific interstitial pneumonia (n 
22). Consecutive patients with biopsy-proven disease performed a
6-minute walk test between January 1996 and December 2001.
Desaturation was defined as a fall in oxygen saturation to 88% or
less during the 6-minute walk test. Desaturation was common (44
of 83 usual interstitial pneumonia and 8 of 22 nonspecific interstitial
pneumonia; chi square, p  0.39). Patients with usual interstitial
pneumonia or nonspecific interstitial pneumonia who desaturated
had a significantly higher mortality than patients who did not desa-
turate (respective log-rank tests, p 0.0018, p0.0089). In patients
with usual interstitial pneumonia, the presence of desaturation was
associated with an increased hazard of death (hazard ratio, 4.2;
95% confidence interval, 1.40, 12.56; p  0.01) after adjusting for
age, sex, smoking, baseline diffusion capacity for carbon monoxide,
FVC, and resting saturation. We conclude that knowledge of desatu-
ration during a 6-minute walk test adds prognostic information for
patients with usual interstitial pneumonia and nonspecific intersti-
tial pneumonia.
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As a group, patients with usual interstitial pneumonia (UIP)
have a poor prognosis (a median survival of 2.8 to 4.0 years)
(1–4). The prognosis for any individual patient, however, is vari-
able. As such, additional predictors of survival are important to
help patients and physicians stratify the risks and benefits of
therapeutic endeavors, including experimental protocols, cyto-
toxic therapies, and lung transplantation. Recent studies have
identified demographic (age, smoking, sex), physiologic (diffu-
sion capacity for carbon monoxide [DlCO], FVC, exercise PaO2),
radiographic (amount of fibrosis), and histopathologic features
(fibroblastic foci) that are associated with survival (2, 5–11).
A central feature in the pathophysiology of idiopathic pulmo-
nary fibrosis (IPF) is impaired gas exchange that worsens with
exercise (1, 12). Exercise-induced widening of alveolar arterial
O2 gradient and a fall in arterial Po2 are secondary to multiple
abnormalities, including ventilation/perfusion mismatching, O2
diffusion limitation, low mixed venous Po2, and right-to-left in-
tracardiac shunting through a patent foramen ovale (13–17). PaO2
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with exercise (2) and at rest (18) has been shown to predict
survival in patients with UIP.
A simple test to evaluate desaturation with exertion is a 6-
minute walk test (6MWT) (19, 20). Desaturation of hemoglobin,
as measured by pulse oximetry, during a 6MWT is predictive of
mortality in patients with primary pulmonary hypertension (21).
We hypothesized that desaturation during a 6MWT would pro-
vide additional prognostic information regarding survival for
patients with UIP and nonspecific interstitial pneumonia (NSIP)
after accounting for demographic, physiologic, and radiographic
features. Some of the results of this study have been reported
in the form of an abstract (22).
METHODS
Patient Selection
Consecutive patients with surgical lung biopsy–confirmed UIP and
NSIP who underwent a 6MWT on room air between January 1996 and
December 2001 formed the study group. This study used patients from
the University of Michigan Specialized Center of Research in the Pa-
thobiology of Fibrotic Lung Disease database. The slides were reviewed
by two independent pathologists, and the diagnoses of UIP and NSIP
were based on American Thoracic Society/European Respiratory Soci-
ety guidelines (23). Patients with underlying collagen vascular disease
or occupational exposure were excluded. A subgroup of these patients
has been previously described (7). Approval for the use of these data
was obtained from the Institutional Review Board of the University of
Michigan.
Pulmonary Function Testing and High-resolution
Computed Tomography
Pulmonary function tests, including spirometry and DlCO, were per-
formed as previously described (24). High-resolution computed tomog-
raphy examinations were performed and semiquantitatively scored for
ground-glass opacity and interstitial opacity (computed tomography
fibrosis score [CT-fib]) as previously described (7, 25). The radiologists
were unaware of the histologic diagnosis at the time of interpretation.
6MWT
The protocol used for the 6MWT was designed to ensure an accurate
assessment of oxygen desaturation and to provide a clinically useful
oxygen titration. All patients were tested under standardized conditions
in the same pulmonary function laboratory by trained technicians who
were blinded to the histologic diagnosis. Baseline blood pressure, heart
rate, and oxygen saturation using Nellcore pulse oximetry (Nellcore
N-3000; Mallinckrodt Inc., Hazelwood, MO) were measured. If the
resting saturation was less than 88% on room air, patients were not
considered eligible for room air 6MWT. These patients were excluded
from the study group.
Patients were instructed as follows: “The object of this test is to
walk as quickly as you can for 6 minutes to cover as much ground as
possible. You may slow down if necessary. If you stop we wish you to
continue the walk again as soon as possible. Your goal is to walk as fast
and as far as you can in 6 minutes.” To ensure an accurate assessment of
the oxygen saturation, the respiratory therapist checked that the pulse
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oximeter had an acceptable signal and that the oximeter bar was pulsing
to show the heart rate and was in synchrony with the heart rate before
beginning all tests. Fingernail polish, if worn by the patient, was re-
moved before testing. Patients walked on a level surface with gentle
encouragement using set phrases every 30 seconds. SaO2 was measured
continuously during the walk. If the patient experienced an oxygen
saturation of 88% persistent for 1 minute or if saturation fell below
87%, the study was repeated with supplemental oxygen administered
using a threshold similar to that of other investigators in this field (26,
27) and following published recommendations (28). Maximal distance
was defined as the maximal achieved walk distance during room air or
oxygen-supplemented 6MWT.
Statistical Analysis
Categorical data were compared using chi-square tests (29), and contin-
uous data were compared using two-tailed t tests (30). All t tests assumed
unequal variances with p values of less than 0.05 considered statistically
significant. Vital status, ascertained as of June 2002, was determined
by review of electronic patient charts and review of the most recent
social security death index. Survival experiences for desaturation status
groups were illustrated via Kaplan-Meier curves (31). Four patients
underwent lung transplantation and were censored on the date of trans-
plantation. Cox regression analysis (32) was used to examine the rela-
tionship between desaturation and mortality, adjusting for demographic
characteristics (age, sex, and smoking status), physiologic data (FVC,
DlCO, resting SaO2) and radiographic variables (CT-fib). For the purpose
of data analysis, desaturation was defined as fall in SaO2 equal to or
below 88% during the room air 6MWT (27, 28). Additional analyses
were performed with decrease in saturation ( sat  resting saturation
 lowest saturation on 6MWT) expressed as a continuous variable or
as a 4% decrease from the baseline saturation ( sat of 4% or more). A
logistic regression analysis (33) was used to determine whether baseline
demographic, physiologic, radiographic, or histopathologic information
could predict desaturation.
RESULTS
Of the 123 patients who underwent 6MWT during the study
period, 18 (UIP  15, NSIP  3) were excluded, as their resting
saturations were less than 88%, and hence, they did not undergo
a room air 6MWT. One hundred and five patients (UIP  83,
NSIP  22) made up the study group. Table 1 compares the
physiologic and walk test characteristics seen in the two cohorts.
Thirty-eight UIP and eight NSIP patients met criteria for oxygen
supplementation.
A similar proportion of patients with UIP (44 of 83, 53%)
and NSIP (8 of 22, 36%) desaturated (chi square, p  0.17). No
significant differences were noted in age, sex, smoking history,
or treatment given between patients with UIP or NSIP who
desaturated versus those that did not desaturate. Similarly, there
was no significant difference in the interval between open lung
TABLE 1. PHYSIOLOGIC AND 6-MINUTE WALK TEST
FEATURES OF PATIENTS WITH USUAL INTERSTITIAL
PNEUMONIA AND NONSPECIFIC INTERSTITIAL PNEUMONIA
Characteristic UIP (n  83) NSIP (n  22) p Value
Resting saturation, % 95.6  1.0 96.0  2.5 0.48*
 Saturation, % points 7.1  4.1 5.7  4.1 0.17*
Desaturation 44 (53%) 8 (36%) 0.17†
 Saturation  2% 75 (90%) 20 (90%) 0.94†
 Saturation  4% 66 (80%) 14 (64%) 0.12†
Maximal distance, ft 1,166  355 1,174  313 0.92*
Definition of abbreviations: desaturation  oxygen saturation of 88% or less on
the 6MWT; NSIP  nonspecific interstitial pneumonia;  saturation  resting
saturation  lowest saturation on 6MWT; UIP  usual interstitial pneumonia.
* t test (unequal variances).
† 2 test.
biopsy and walk test between those who desaturated versus those
that did not desaturate (mean biopsy–walk interval: desaturators
7.84  18.01 months [n  52], nondesaturators 7.67  16.09
months [n  53], p  0.95). Patients with UIP who desaturated
exhibited significantly lower values of FVC, DlCO, and resting
saturation than patients with UIP who did not desaturate. No
significant difference in pulmonary function was noted between
patients with NSIP who did and did not desaturate, although
there was a trend toward a lower DlCO in the group that desatu-
rated. The small number of patients with NSIP may have limited
our ability to detect statistically significant differences. Resting
saturation was significantly lower in patients with NSIP that
desaturated (Table 2).
DlCO (odds ratio of 0.50 for a 10-unit increase in DlCO percent-
age predicted; 95% confidence interval [CI], 0.32–0.78; p 0.002)
and resting saturation (odds ratio of 0.41 for 1% increase in
resting saturation; 95% CI, 0.41–0.87; p  0.0066) were signifi-
cant predictors of desaturation after adjusting for age, sex, smok-
ing history, CT-fib score, and FVC in patients with UIP. No
significant predictors of desaturation were identified in the group
with NSIP.
The median follow-up period was 2.93 years (range of 0.1 to
5.7 years) in the UIP group and 3.63 years (0.32 to 5.6 years)
in the NSIP group. Patients with UIP or NSIP who desaturated
had a significantly higher mortality than patients that did not
desaturate (log-rank test, p  0.0018, p  0.0089) (Figures 1
and 2). The 4-year survival rate was higher in the group that
did not desaturate on 6MWT (Table 3).
Univariate analysis was performed using variables that have
been suggested to influence survival in previous studies of pa-
tients with UIP (Table 4). The lack of deaths in the patients
with NSIP who did not desaturate precluded further analysis in
this subset of patients. The presence of desaturation (hazard
ratio [HR], 3.25; 95% CI, 1.47–7.2; p 0.0016), lower FVC (HR
for a 1-L increase, 0.65; 95% CI, 0.42–1.00; p  0.05), and lower
FEV1 (HR for a 1-L increase 0.58; 95% CI, 0.33–0.99; p  0.04)
were found to be significant predictors of mortality. Importantly,
after adjusting for age, sex, smoking history, baseline DlCO per-
cent predicted, FVC percent predicted, resting saturation, and
histologic diagnosis, desaturation on 6MWT remained a signifi-
cant predictor of mortality in all patients (UIP and NSIP) (HR,
4.47; 95% CI, 1.58–12.64; p  0.005) (Table 5) and when the
analysis was repeated only in UIP patients (HR, 4.20; 95% CI,
1.40–12.56; p  0.01) (Table 5). The strength of this association
was maintained after adjusting for high-resolution computed
tomography fibrotic scores (data not shown).
In additional analyses, we examined alternative approaches
to defining a fall in saturation during a 6MWT;  saturation
(resting saturation lowest saturation on 6MWT as a continuous
parameter) was a significant predictor of mortality in both uni-
variate (HR, 1.18; 95% CI, 1.08–1.28; p 0.003) and multivariate
analysis (HR, 1.23; 95% CI, 1.08–1.40; p  0.0004). For each
percentage decrease in saturation, mortality increased by 23%.
As others have suggested that a decrease in saturation of 4% is
clinically significant (1, 34), we explored this threshold. A de-
crease in saturation of 4% or more ( saturation of four or
more) was a significant predictor of mortality in multivariate
analysis (HR, 13.58; 95% CI, 1.71–107.54; p  0.01).
DISCUSSION
In this study, we examined the relationship between desaturation
during a 6MWT and survival in patients with UIP and NSIP.
We found that desaturation was strongly predictive of mortality.
In patients with UIP, after adjusting for age, sex, smoking history,
baseline DlCO percent predicted, FVC percent predicted, resting
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TABLE 2. DEMOGRAPHIC, PHYSIOLOGIC, AND HIGH-RESOLUTION COMPUTED TOMOGRAPHY
FEATURES OF USUAL INTERSTITIAL PNEUMONIA AND NONSPECIFIC INTERSTITIAL PNEUMONIA
Usual Interstitial Pneumonia Nonspecific Interstitial Pneumonia
No Desaturation, Desaturation, No Desaturation, Desaturation,
n  39 n  44 n  14 n  8
Variable (mean  SD) (mean  SD) p Value (mean  SD) (mean  SD) p Value
Demographics
Age, yr 63  11 61  9 0.29† 57  9 61  10 0.33†
Sex, male/female 20/19 24/20 0.76‡ 8/6 6/2 0.40‡
Smokers, % 69 68 0.92‡ 64 63 0.93‡
Cigarette
consumption,
pack years 24 (4–92)* 21.5 (4–80)* 0.54† 33 (7–90)* 36 (14–53)* 0.78†
Treatment 0.79‡ 0.19‡
No treatment 3 1 2 1
Prednisone 6 8 4 3
Prednisone 
azathioprine 16 17 5 0
Azathioprine 12 14 2 2
Miscellaneous 2 4 1 2
Physiologic
FVC, L 2.60  0.93 2.13  0.61 0.0096† 2.52  0.88 3.09 0.72 0.12†
FVC, % predicted 71  21 58  16 0.0055† 68  23 74  14 0.51†
FEV1, L 2.17  0.75 1.80  0.49 0.0089† 1.93  0.66 2.33 0.47 0.11†
FEV1, % predicted 83  24 68  17 0.0027† 70  22 79  15 0.31†
DLCO ml/min/mm Hg 15.00  5.33 10.42  3.22  0.0001† 13.73  4.66 10.98 3.90 0.16†
DLCO, % predicted 59  18 42  12  0.0001† 57  22 42  13 0.06†
Resting saturation, % 96.31  1.76 94.95  2.03  0.0017† 97  1.66 94.3 2.76 0.03†
HRCT
CT-fib score 1.68  0.55 1.78  0.76 0.50† 1.16  0.82 0.98 0.64 0.64†
Definition of abbreviations: CT-fib  semiquantitatively scored interstitial opacity on high-resolution computerized tomography
(25); DLCO carbon monoxide diffusion capacity; HRCThigh-resolution computerized tomography; NSIP nonspecific interstitial
pneumonia; UIP  usual interstitial pneumonia.
* Median (range).
† t test (unequal variances).
‡ 2 test.
Patients are stratified by the presence or absence of desaturation (oxygen saturation OF 88% or less) on a 6-minute walk test.
saturation, and the amount of fibrosis on high-resolution com-
puted tomography, the presence of desaturation was associated
with a greater than fourfold hazard of death. Furthermore, all
deaths in patients with NSIP occurred in patients who desatu-
rated. We also demonstrate that desaturation is frequently noted
in both patients with UIP (44 of 83, 53%) and NSIP (8 of 22,
36%). A significant predictor of desaturation in patients with
UIP was DlCO after adjusting for age, sex, smoking history,
Figure 1. Kaplan-Meier survival curve for patients with usual interstitial
pneumonia (UIP) grouped by desaturation (oxygen saturation of 88%
or less) on 6MWT (desaturators, dashed line; nondesaturators, solid line;
p  0.0018).
FVC, and the amount of fibrosis on high-resolution computed
tomography.
Our data demonstrate that UIP patients who desaturate dur-
ing a 6MWT had a more than fourfold higher hazard of dying
during follow-up. The prognostic importance of exercise-induced
hypoxia has been suggested in the literature (2, 35). In the clinical
radiologic physiologic scoring system devised to predict survival
in IPF, resting gas exchange was not important; however, exer-
cise PaO2 on cardiopulmonary exercise testing was significantly
predictive of survival and accounted for as much as 10.5% of
the maximum in predicting survival (2). More recently, in a study
of 41 patients with IPF, exercise induced hypoxemia evaluated
by PaO2/V˙o2 on cardiopulmonary exercise testing was strongly
correlated with survival (35). Importantly, other investigators
have not confirmed that cardiopulmonary exercise testing mea-
sures of gas exchange provide additional prognostic value in IPF
patients (24, 36). Furthermore, registry data suggest that exercise
testing is infrequently used in clinical practice to evaluate pa-
tients with IPF (37). This may relate to the expense and limited
availability of this diagnostic modality. In contrast, 6MWT is a
simple, inexpensive test that is convenient, requires minimal
medical personnel, and can be performed in an office setting
(28). Moreover, a good correlation has been demonstrated be-
tween O2 uptake and peak PaO2 between cardiopulmonary exer-
cise testing and 6MWT (38). Furthermore, in a study of 80
consecutive patients with COPD, 6MWT was found to be more
sensitive than maximal incremental cycle testing in detecting
desaturation defined as fall in saturation of 4% or more by pulse
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Figure 2. Kaplan-Meier survival curve in patients with nonspe-
cific interstitial pneumonia (NSIP) grouped by desaturation
(oxygen saturation of 88% or less) on 6MWT (desaturators,
dashed line; nondesaturators, solid line; p  0.0089).
oximetry (34). These investigators also confirmed the reproduc-
ibility of changes in pulse oximetry on repeat 6MWTs. This is
not surprising, as pulse oximetry has been found to be accurate
within 2% (1 SD) or 5% (2 SD) of in vitro oximetry in the
range of 70% to 100% SaO2 (39). Our data demonstrate that
desaturation on 6MWT in patients with UIP and NSIP portends
a bad prognosis and provides compelling support for the routine
use of this technique in patients with UIP and NSIP.
We demonstrate a strong correlation of measures of fall in
saturation on a 6MWT and survival independent of the format
used to define desaturation. A decrease in saturation below 88%
has been used by others examining gas exchange in interstitial
disease (27) and to identify patients requiring oxygen supplemen-
tation during exercise (28). Importantly, the use of this threshold
in our data set provides two equally distributed groups with very
different survival rates. The 4-year survival rate of UIP patients
who desaturated to this level was 34.5% compared with 69.1%
in patients who did not desaturate. The use of a change in
saturation as a continuous variable confirms the strong predictive
ability of desaturation during 6MWT to predict a less favorable
outcome; for each 1% decrease in saturation, mortality increased
by 23%. A recent American Thoracic Society consensus state-
ment suggested a 4% decrease in saturation during exercise as
an adverse prognostic sign in IPF (1). Our data provide support
for this, as patients experiencing such a level of desaturation
exhibited a nearly 14-fold increase in mortality, albeit with a
wide confidence interval. The latter likely reflects that most
patients in the current cohort experienced a decrease in satura-
tion of 4% or more, with only one death noted in the 17 patients
who exhibited a decrease in saturation of less than 4%. These
data provide a compelling argument for the clinical use of the
TABLE 3. FOUR-YEAR SURVIVAL RATE FOR PATIENTS WITH
NONSPECIFIC INTERSTITIAL PNEUMONIA AND USUAL
INTERSTITIAL PNEUMONIA
4-Year Survival Rate 95% CI
UIP no desaturation 69.1% 46.2–91.9%
UIP desaturation 34.5% 17.4–51.7%
NSIP no desaturation 100% —
NSIP desaturation 65.6% 24.7–100%
Definition of abbreviations: CI confidence interval; NSIP nonspecific intersti-
tial pneumonia; UIP  usual interstitial pneumonia.
Patients are stratified by the presence or absence of desaturation (oxygen satura-
tion of 88% or less) on a 6-minute walk test.
6MWT in the evaluation of patients with UIP and NSIP. As
the 4-year survival after lung transplantation in IPF patients is
approximately 45% (40), a strong case can be made for referring
UIP patients who meet published criteria (41) and who desatur-
ate during 6MWT. As UIP patients who desaturate experience
a 4-year survival of 34.5%, they are most likely to experience
a survival benefit from lung transplantation. In contrast, UIP
patients who do not desaturate during 6MWT experience a 4-
year survival of 69.1%, suggesting that a delay in listing may
not impair long-term survival in this group.
DlCO was a predictor of desaturation on 6MWT in UIP pa-
tients but did not correlate with mortality in multivariate models.
The prognostic value of the simple 6MWT likely reflects the
cumulative impact of ventilation/perfusion mismatching, O2 dif-
fusion limitation, low mixed venous Po2, and right-to-left intra-
cardiac shunting through a patent foramen ovale that may be
seen in patients with fibrotic lung diseases (13–17). Several au-
thors have suggested a fair correlation between measures of
gas exchange during maximal exercise testing and the extent of
physiologic or radiologic abnormality in patients with pulmonary
fibrosis (42–49). Some have documented modest correlations
between static physiologic parameters and desaturation during
6MWT (50) in patients with interstitial lung diseases. Arterial
oxygen tension during maximal exercise has been correlated
TABLE 4. UNIVARIATE ANALYSIS OF SURVIVAL IN PATIENTS
WITH USUAL INTERSTITIAL PNEUMONIA
Parameter Hazard Ratio (95% CI) p Value
Demographic age, yr 1.00 (0.97–1.04) 0.81
Male sex 1.05 (0.53–2.08) 0.89
Positive smoking history 0.62 (0.31–1.24) 0.18
Physiology FVC, L 0.65 (0.42–1.00) 0.05
FVC, per 10% predicted 0.84 (0.69–1.00) 0.06
FEV1, L 0.58 (0.33–0.99) 0.04
FEV1, per 10% predicted 0.86 (0.73–1.01) 0.07
DLCO ml/min/mm Hg 0.95 (0.87–1.03) 0.21
DLCO, per 10% predicted 0.85 (0.68–1.06) 0.13
Timed walk test desaturation 3.25 (1.47–7.20) 0.0016
Resting saturation 0.91 (0.77–1.08) 0.27
Maximal distance, per 10 ft 0.997 (0.989–1.006) 0.53
HRCT CT-fib 1.23 (0.73–2.07) 0.43
Definition of abbreviations: CI confidence interval; CT-fib semiquantitatively
scored interstitial opacity on high-resolution computerized tomography (25); de-
saturation oxygen saturation of 88% or less on 6MWT; DLCO carbon monoxide
diffusion capacity; UIP  usual interstitial pneumonia.
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TABLE 5. MULTIVARIATE ANALYSIS OF SURVIVAL
Parameter Hazard Ratio (95% CI) p Value
All patients
Age, yr 1.04 (0.99–1.09) 0.09
Male sex 1.18 (0.53–2.63) 0.69
Positive smoking history 0.88 (0.39–1.98) 0.76
DLCO, per 10% predicted 1.04 (0.76–1.42) 0.81
FVC, per 10% predicted 0.86 (0.68–1.08) 0.20
UIP 3.14 (0.91–10.92) 0.07
Resting saturation 0.96 (0.79–1.17) 0.67
Desaturation 4.47 (1.58–12.64) 0.005
UIP patients
Age, yr 1.04 (0.98–1.09) 0.16
Male sex 1.13 (0.49–2.58) 0.78
Positive smoking history 0.79 (0.35–1.83) 0.59
DLCO, per 10% predicted 1.11 (0.80–1.55) 0.53
FVC, per 10% predicted 0.85 (0.67–1.07) 0.17
Resting saturation 1.03 (0.82–1.23) 0.97
Desaturation 4.20 (1.40–12.56) 0.01
Definition of abbreviations: CI  confidence interval; desaturation  oxygen
saturation of 88% or less on 6MWT; DLCO  carbon monoxide diffusion capacity;
UIP  usual interstitial pneumonia.
with DlCO in patients with IPF (51–53). Given the prognostic
value of exercise desaturation in patients with primary pulmo-
nary hypertension (21), it may be that the additional value af-
forded by a measurement of exercise induced desaturation in
UIP and NSIP reflects the contribution of pulmonary hyperten-
sion that is frequently noted in fibrotic lung disease (54). The
simplicity of the 6MWT and its probable ability to assess complex
physiologic interactions and predict prognosis make the 6MWT
an important tool for the management of patients with IPF.
Another novel finding of this study is the documentation that
a fall in saturation during 6MWT is a very common phenomenon
in patients with UIP and NSIP. Ninety percent of the patients
with UIP and NSIP had a fall in saturation of 2% or more, and
desaturation to 88% or less was seen in approximately 50% and
36% of patients with UIP and NSIP, respectively. Gas exchange
during exercise has been suggested as an important pathophysio-
logic abnormality in patients with idiopathic interstitial pneumonia
(1, 12). Although most of the studies evaluating exercise-induced
desaturation have used cardiopulmonary exercise testing, two re-
cent studies have examined saturation during a 6MWT in patients
with interstitial lung disease. Desaturation to 88% or less was
seen in 38% of patients with interstitial lung diseases (33 of 50
with IPF) on a 6MWT (27). Similarly, in a study of 40 patients with
varying interstitial lung diseases (19 IPF patients), eight patients
exhibited a drop of 2–5%, whereas 16 experienced desaturation of
more than 5% on a 6MWT (50). Importantly, our study examines a
large number of patients with specific histologic diagnoses and
confirms that desaturation on a 6MWT is a common finding in
patients with UIP and NSIP.
Another interesting finding of our study was that no differ-
ence was seen in the frequency and degree of fall in saturation
during a 6MWT in patients with UIP and NSIP. Some investiga-
tors have suggested a greater rise in the alveolar arterial O2
during exercise in patients with UIP compared with desquama-
tive interstitial pneumonia, asbestosis, berylliosis, sarcoidosis, or
	-1 antitrypsin–related emphysema (53, 55). In contrast, the
trough saturation was similar in a retrospective series of patients
with NSIP (n  14) compared with UIP (n  63); the mode of
exercise testing or proportion with desaturation was not de-
scribed (3). In our study, we found no statistical difference in
any of the variables obtained during a 6MWT, including resting
saturation, various degrees of fall in saturation, and maximal
distance walked in patients with NSIP and UIP. Together, these
studies suggest that desaturation on 6MWT in patients with UIP
and NSIP is seen more frequently than other pulmonary diseases
and occurs with similar frequency in patients with UIP and NSIP.
In conclusion, desaturation during a 6MWT is a strong pre-
dictor of mortality in patients with UIP and NSIP. This effect
persists after adjustment for patient demographic factors, static
physiologic testing, and the amount of fibrosis on high-resolution
computed tomography. This simple exercise modality, which can
be easily obtained in an outpatient setting at a low cost, may be
particularly important in prognostication in patients with UIP
and NSIP and may help optimize referral and listing of patients
for lung transplantation. Our data also suggest that desaturation
on a 6MWT could be used for stratification of patients with UIP
in clinical trials, as these two groups exhibit a very different
survival profile. Further research is required to determine the
role of serial measures of 6MWT in the follow-up of patients
with UIP and whether desaturation on a 6MWT can be used as
a surrogate for survival in phase II trials. Although 6MWT has
been suggested as a measure of functional capacity with distance
as the primary endpoint, our data confirm that documentation
of desaturation offers important information in patients with
UIP and NSIP.
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